The unbearable grief of losing their baby girl, Lupine, just weeks after her birth, has transformed into a powerful mission for parents Alexandre Genest and Carly Wedge. Their heartbreak stems from a devastating encounter with Group B Streptococcus, or GBS, which rapidly progressed to sepsis and meningitis. As the article states, their daughter, who was described as ‘perfectly healthy’ with ‘long hair already’ and ‘big, sparkly eyes,’ fell suddenly ill and passed away within days. Now, instead of succumbing to their sorrow, this resilient couple is advocating for a promising development: a new maternal GBS Vaccine that could prevent such tragedies from hitting other families. This is ‘straight up’ a story of turning profound loss into action.
GBS, while often harmless in adults, can be life-threatening for newborns. According to the report, pregnant women are typically screened for GBS, and if positive, receive antibiotics during labor. This measure can protect infants during their first week of life, but it falls short for cases like Lupine’s, where the illness strikes later in infancy. The lack of prevention for these later-onset infections highlights a critical gap in infant care, a void the medical community has long sought to fill. This is where the potential of a comprehensive vaccine truly ‘hits different’, offering a broader shield against this insidious bacterium.
A significant breakthrough is now within reach, thanks to advancements in vaccine development. Dr. Joanne Langley, a pediatric infectious disease specialist at the IWK Health Centre, where Lupine was treated, and an investigator at the Canadian Center for Vaccinology, is actively involved in a Phase 3 clinical trial for a maternal GBS vaccine. She emphasizes that preventing the disease is the ‘best strategy,’ given GBS’s rapid escalation, often overwhelming even the best treatments before they can take effect. This vaccine represents a massive leap forward in protecting our tiniest, most vulnerable population.
The journey to a GBS vaccine has been a long one, with researchers working on it since the 1970s, as the article mentions. However, Dr. Langley confirms that the current Pfizer trial is the most advanced effort to date. If the trial progresses successfully and regulatory approvals are secured, she believes this vaccine could be widely available within the next few years. This would represent an ‘overwhelming advance’ in the care of both women and babies, offering hope for a future where fewer families experience the pain of GBS-related infant loss. ‘No cap,’ this could change everything for parents-to-be.
Globally, the impact of GBS is staggering. The World Health Organization (WHO) reports that GBS is responsible for approximately 150,000 stillbirths and infant deaths worldwide each year. The introduction of a vaccine could potentially prevent more than 50 percent of infant GBS cases. Furthermore, GBS has been linked to preterm births, and the WHO suggests a vaccine could also lower this risk, contributing to healthier pregnancies and safer deliveries across the globe. The ripple effect of such a preventative measure is immense.
Beyond saving lives, the vaccine could also lead to a reduction in antibiotic use for pregnant women who test positive for GBS. Dr. Langley points out that this is beneficial for maintaining the mother’s ‘healthy’ microbiome on her skin and in her vagina, which in turn contributes to the newborn’s developing microbiome. This holistic benefit underscores the comprehensive advantages of vaccination over current treatment protocols, promoting better long-term health outcomes for both mother and child.
The Pfizer vaccine trial is extensive, operating at over 200 sites worldwide, including four in Canada. Carly Wedge expressed a sense of ‘serendipity’ that the clinical trial began in Nova Scotia shortly after Lupine’s passing. She has become deeply passionate about ensuring that ‘something is done’ to prevent other families from enduring similar experiences, highlighting the personal drive behind her public advocacy for this crucial medical research. This mission is ‘for real’ and deeply personal for them.
Alexandre Genest and Carly Wedge are actively cycling Nova Scotia’s roads and trails, pulling a small trailer adorned with Lupine’s picture. Through this journey and their social media presence, they are openly sharing their story, finding it healing to talk about their daughter. Their ultimate goal is to generate interest in the vaccine trial and help local investigators, who aim to enroll 30 participants, meet their target. They are spreading the word ‘to help them push the science forward,’ ensuring this vital research gets the support it needs.
While the promise of the vaccine is huge, Dr. Langley also offered a necessary heads-up about the ongoing trial. As the vaccine is new, its long-term risks are not fully known, with the current study primarily focused on establishing its safety. So far, investigators have not observed any serious events associated with the shot. However, she noted that an additional trial might be required to definitively test the vaccine’s efficacy in preventing the disease itself. This staged approach is standard in vaccine development, ensuring thoroughness and public safety.
If you enjoyed this article, share it with your friends or leave us a comment!
Adrian Velk is a global affairs journalist focused on breaking news, geopolitics, and societal trends. With a sharp eye for detail and a commitment to accuracy, he delivers timely reporting that helps readers understand the fast-moving world around them. His work blends factual depth with clear storytelling, making complex events accessible to a broad audience.
